Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement

Area of Science:

• Neuropharmacology
• Behavioral Neuroscience

Background:

• Dopamine receptors play a crucial role in regulating motor functions.
• Bromocriptine (BRC) is a known dopamine D-2 receptor agonist with potential behavioral effects.

Purpose of the Study:

• To investigate the ability of bromocriptine (BRC) to induce climbing behavior in mice.
• To elucidate the specific dopamine receptor subtypes involved in BRC-induced climbing.

Main Methods:

• Administration of varying doses of BRC to mice.
• Assessment of climbing behavior following BRC administration.
• Evaluation of the effects of dopamine antagonists (pimozide, sulpiride, SCH 23390) and receptor depletors (reserpine, AMPT) on BRC-induced climbing.
• Investigating interactions with other dopamine agonists (apomorphine, SKF 38393).

Main Results:

• BRC dose-dependently induced climbing behavior, with an optimal dose of 8 mg/kg.
• Climbing behavior peaked approximately 5 hours post-injection.
• Dopamine antagonists (pimozide, sulpiride, SCH 23390) significantly reduced BRC-induced climbing.
• Pretreatment with reserpine plus AMPT abolished the climbing response.
• Interactions with apomorphine and SKF 38393 indicated complex modulatory effects on dopamine receptor signaling.

Conclusions:

• Bromocriptine induces climbing behavior in mice, suggesting a role for dopamine receptor activation.
• The findings implicate both D-1 and D-2 dopamine receptors in mediating this behavioral response.
• BRC's effects are modulated by other dopaminergic agents, highlighting the intricate interplay within the dopamine system.